2023
11
July
2023
|
09:29
Europe/Amsterdam
In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study investigators, Dr. Hyo-Soo Kim presented the results of a stent level analysis comparing two ultrathin strut drug-eluting stents (DES): Orsiro® and Corofl...
Read more
2022
05
July
2022
|
10:14
Europe/Amsterdam
A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and safety of three contemporary DES including BIOTRONIK’s ultrathin struts drug-eluting stent (DES) Orsiro® at 5 years. The results of the analysis ...
Read more
28
February
2022
|
14:27
Europe/Amsterdam
BIOTRONIK today announced five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking-clinical-trial session by Dr. David Kandzari, US Principal Investigator, Piedmont Heart Institute, Atla...
Read more
2021
15
March
2021
|
14:42
Europe/Amsterdam
BIOTRONIK’s ultrathin-strut stent, Orsiro®*, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 months, according to new follow-up data from the BIOSTEMI trial.1The latest results were presented by Prof. Thomas Pilgrim, In...
Read more
2020
06
May
2020
|
09:24
Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro® drug eluting stent (DES) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monot...
Read more
24
February
2020
|
00:00
Europe/Amsterdam
BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinfo...
Read more
2019
30
October
2019
|
00:00
Europe/Amsterdam
BIOTRONIK announced today that its Orsiro® coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device available to Chinese patients and physicians in t...
Read more
18
October
2019
|
14:54
Europe/Amsterdam
About 30 percent of patients undergoing primary percutaneous coronary intervention (PCI) suffer from ST-Elevation Myocardial Infarction (STEMI) – the most acute form of coronary artery disease. It’s caused by a complete thrombotic occlusion and is as...
Read more
21
May
2019
|
00:00
Europe/Amsterdam
Focusing on patients with small vessels, three-year outcomes of the BIO-RESORT randomized controlled trial (RCT) showed a significantly lower target lesion revascularization (TLR) rate and thus better efficacy of the Orsiro® drug-eluting stent1 (DES)...
Read more
06
March
2019
|
00:00
Europe/Amsterdam
Three-year outcome data from the BIO-RESORT1 randomized controlled trial were presented in a late-breaking clinical trials session by Dr. Clemens von Birgelen, Thoraxcentrum Twente, MST, Enschede, The Netherlands. Results from this large three-arm tr...
Read more
25
February
2019
|
00:00
Europe/Amsterdam
BIOTRONIK today announced FDA approval of the Orsiro drug-eluting stent (DES) system. Orsiro is the first and only ultrathin DES to outperform the clinical standard, Xience.1,2 Orsiro received CE marking in 2011 and has been used to treat more than o...
Read more
2018
20
November
2018
|
00:00
Europe/Amsterdam
Following a statistical calculation error, the outcomes of SORT-OUT IX1 have recently been corrected, resulting in a change to the trial’s primary endpoint. The revised data analysis demonstrates that compared to BIOTRONIK’s Orsiroa drug-eluting sten...
Read more
25
September
2018
|
00:00
Europe/Amsterdam
Investigators unveiled clinical data from the independent BIONYX1 and SORT OUT IX2 all-comers trials which respectively compared durable polymer Resolute Onyxb and polymer-free BioFreedomc to bioresorbable polymer Orsiro.
In both studies, patients...
Read more
24
September
2018
|
00:00
Europe/Amsterdam
Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiro and Xience1 drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro across a range of clinical endpoi...
Read more
24
May
2018
|
00:00
Europe/Amsterdam
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials session by Dr. Marlies M. Kok, Thoraxcentrum Twente, MST, Enschede, the Netherlands and simultaneously published in EuroInterventi...
Read more
27
March
2018
|
00:00
Europe/Amsterdam
Dr. Yang Yue Jin, Professor of Cardiology at the Fu-Wai Hospital, National Center of Cardiovascular Disease, Beijing, China, presented the 9- and 12-month results of the BIOFLOW-VI clinical study at the China Interventional Therapeutics (CIT) 2018 co...
Read more
13
March
2018
|
00:00
Europe/Amsterdam
BIOTRONIK announced today that patient enrollment for the BIOSTEMI study has been completed. STEMI is a potentially fatal type of heart attack, caused by prolonged obstruction of blood supply in the heart. More than 730,000 cardiac artery disease (CA...
Read more
22
January
2018
|
00:00
Europe/Amsterdam
BIOTRONIK announced today market approval for its Orsiro1 coronary drug-eluting stent (Orsiro DES) by the Japanese Ministry of Health. This was supported by the positive 12-month outcomes of the BIOFLOW-IV clinical study which were presented at the 8...
Read more
2017
02
November
2017
|
00:00
Europe/Amsterdam
BIOTRONIK’s Orsiro1 drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during TCT 2017.
Data from the BIOFLOW-II randomized controlled trial was presented in a poster...
Read more
31
October
2017
|
00:00
Europe/Amsterdam
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the cas...
Read more
28
August
2017
|
00:00
Europe/Amsterdam
BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority. Results presented at the European So...
Read more
20
March
2017
|
00:00
Europe/Amsterdam
BIOTRONIK, a leading manufacturer of cardio- and endovascular technology, presented 12-month results of the BIOFLOW-IV multi-center clinical study at this year’s Japan Circulation Society congress. The BIOFLOW-IV study is a prospective multi-center, ...
Read more
